Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: Primary To determine the efficacy and safety of first-line immune checkpoint inhibitors, or immuno-oncology therapy (IO), as monotherapy or in combination for patients with advanced non-small cell lung cancer (NSCLC). Secondary To maintain the currency of evidence by taking a living systematic review approach.

Original publication

DOI

10.1002/14651858.CD013257

Type

Journal article

Journal

Cochrane Database of Systematic Reviews

Publication Date

06/02/2019

Volume

2019